Reata Pharmaceuticals Inc(RETA)stock report

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich’s ataxia, mitochondrial myopathies and metastatic melanoma.


Current cash: 280M, Latest quarter loss:34.38M,去年亏损80.55M,够烧3年。

EPS and Sales:

Date EPS % last year % last quarter
 2018.9.30 -2.03 -51.49% -54.68%
2018.12.31 -2.91 -46.23% -43.35%
 2019.3.31 -0.98 -712.50% 66.32%
2019.6.30 -2.12 -130.43% -116.33%


Date Sales % last year % last quarter
2018.12.31 45.14M 18.49% 11.48%
 2019.3.31 53.59M 11.51% 18.72%
2019.6.30 7.77M -76.01% -85.50%
 2019.9.30 15.6M -60.96% 100.77%


Insider Transactions:
Institution Ownership:


Analyst Ratings:

Leave a Reply